Skip to content

Safety and Efficacy of Combined Sedation With Midazolam and Dexmedetomidine in ICU Patients

Safety and Efficacy of Combined Sedation With Midazolam and Dexmedetomidine in ICU Patients

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02080169
Enrollment
600
Registered
2014-03-06
Start date
2014-02-28
Completion date
2014-12-31
Last updated
2014-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium

Keywords

Intensive care unit, Mechanical ventilation, Combined sedation

Brief summary

It is well known that ICU patients need sedation. Now no ideal sedation drug existed and every sedation drug has its advantage and disadvantage,so combined sedation may use the advantage and avoid the disadvantage of the sedation drug according to the patients'condition. Until now, there is rare study about the combined sedation or sequenced sedation of different sedation drug.The purpose of the study is to explore the value of combined sedation with midazolam and dexmedetomidine compared to single drug sedation in ICU, so as to seek an ideal sedation protocol that could reduce the cost of treatment,obtain the appropriate sedation not under sedation or over sedation,reduce the incidence of delirium, reduce the adverse event of sedation.

Interventions

DRUGmidazolam

If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained. If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained.

DRUGDexmedetomidine

If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained. If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained.

DRUGFentanyl

Fentanyl is used as analgesic drug in order to obtain the VAS \<3.

Sponsors

Chinese Medical Association
CollaboratorNETWORK
Qilu Hospital of Shandong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. ICU patients needing sedation 2. 18 years or older 3. mechanically ventilated for less than 96 hours prior to start of study drug.

Exclusion criteria

1. Trauma and burn patients as admitting diagnosis. 2. Dialysis of all types. 3. Pregnant or lactation. 4. Neuromuscular blockade other than for intubation. 5. Epidural or spinal analgesia. 6. General anesthesia prior to or planned after the start of study drug infusion 7. Serious central nervous system pathology(acute stroke, uncontrolled seizures,severe dementia). 8. Acute hepatitis or severe liver disease (Child-Pugh class C). 9. Unstable angina or acute myocardial infarction. 10. Left ventricular ejection fraction less than 30%,heart rate less than 50/min. 11.Second or third degree heart block. 12.Allergy to the study drug. 13.Systolic blood pressure less than 90 mm Hg despite continuous infusions of 2 vasopressors before the start of study drug infusion. 14\. Patients with renal insufficiency were randomized and treated; however, patients were discontinued if they required dialysis.

Design outcomes

Primary

MeasureTime frameDescription
The total time within target sedation levelFrom sedation drug is used to weaning from sedation up to 28 days.1. Sedation level with RASS score is recorded every 4 hours during sedation. 2. When target sedation was not obtained, sedation drug dosage changed and when adverse event needed to be treated, the sedation level is also recorded. 3. The adjustment of sedation drug is recorded.

Secondary

MeasureTime frameDescription
Duration of mechanical ventilationFrom beginning to weaning from ventilation up to 28 days..The duration of mechanical ventilation is recorded.
Economic outcomeFrom admitted to ICU until ventilation and sedation stopped and participants discharged from ICU up to 28 days.The cost of sedation drug used is recorded. The cost of mechanical ventilation is recorded. The cost of ICU residency is recorded.
Satisfactory of patients to ICU stay from admitted until discharged from ICUAssessed at time of 1 week participants discharged from ICU.Evaluated the satisfactory of patients to ICU. Using scores including 0 to 10. 0 presents extremely dissatisfied and 10 presents extremely satisfied.
The dosage of sedation/analgesic drugFrom sedation/analgesic drug is used to weaning from sedation/analgesic up to 28 days.Record the induced and maintained dosage of sedation/opioid analgesic drug. The total dosage of sedation/opioid analgesic drug. The added dosage of midazolam.
Vital signsFrom sedation drug is used to weaning from sedation, up to 28 days.Heart rate(HR),main arterial pressure(MAP),respiratory rate(RR),pulse saturate of oxygen(SPO2) are recorded every 4 hours. When sedation drug dosage changed and adverse events treated,the vital signs is also recorded. Gas blood analysis index is recorded when the daily interruption is done and when the SPO2 is less 90% or 10% decrease than normal.
Duration of ICU stayFrom date of admission until participants discharged from ICU up to 28 days.Record when participants discharged form ICU.
DeliriumFrom sedation drug is used to weaning from sedation, up to 28 days.Delirium is evaluated when daily sedation interruption is done during sedation. Delirium incidence is recorded using CAM-ICU. Treatment of delirium is recorded including drug,dosage and method of administration.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026